Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer.

Ryota ShibakiShuji MurakamiYuki ShinnoYuji MatsumotoYasushi GotoShintaro KandaHidehito HorinouchiYutaka FujiwaraNoriko MotoiNoboru YamamotoYuichiro Ohe

Published in: Thoracic cancer (2019)

The presence of MPE in patients administered an anti-PD-1 antibody is associated with shorter PFS and OS, regardless of the presence of PD-L1 expression ≥ 1% of tumor cells.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes